The Scientist’s Post

In this webinar, learn how a novel immunoassay kit and multiplex platform streamlines biomarker screening, saving researchers time and preserving their precious samples. #AD Register today: https://ow.ly/qFJH50REU7o

Streamline your screening projects. Listen to this on-demand webinar with The Scientist to hear from our and Luminex’s expert scientists and learn how combining the new MILLIPLEX® PLEXpedition screening assays with the xMAP® INTELLIFLEX® system can streamline your protein #biomarker screening. Watch now to see how easy it is to measure up to 115 biomarkers at once.

Streamline your screening projects. Listen to this on-demand webinar with The Scientist to hear from our and Luminex’s expert scientists and learn how combining the new MILLIPLEX® PLEXpedition screening assays with the xMAP® INTELLIFLEX® system can streamline your protein #biomarker screening. Watch now to see how easy it is to measure up to 115 biomarkers at once.

A great opportunity to see firsthand how Omni automation has helped the group at Pfizer. If you are in town for WRIB conference, definitely check out this talk!

Early detection shapes outcomes. Find top biomarkers with our flexible, expert assays. The identification of top-performing biomarkers, crucial for early detection, demands a flexible approach. Ensure you have access to flexible expertise when it comes time to develop your assays for biomarker discovery. Read High-Resolution MSD & MS in Clinical Biomarker Validation and discover cutting edge techniques for biomarker discovery. #clinicaltrials #FDA #biotech #pharma #massspec

Unbiased evaluation of the global state of the complement system in various disease contexts has become essential, paving the way for targeted therapeutics, personalized treatment strategies, and improved patient outcomes. Discover our Svar Complement Biomarkers assays, trusted by the scientific community to assess and establish complement biomarkers across diverse diseases. Explore the possibilities: https://hubs.ly/Q02pXgbC0 Key Features: ✔️ Guided by specific neoepitopes: Ensuring precision and accuracy in the complexity of the complement system. ✔️ Speed and Precision: With ready-to-use reagents and short incubation times, get reliable and objective results in as little as 2 hours. ✔️ Objective Result Interpretation: The ELISA format allows for automatization, further reducing variability and ensuring a standardized and objective analytical approach. Remove uncertainty, reduce time, and secure specificity! #ComplementSystem #Biomarkers #ComplementingLifeScience #AnswersinLifeScience #ComplementBiology

Register now to catch our upcoming webinar! Learn about advanced techniques such as ZooMAb® recombinant antibodies, Duolink® Proximity Ligation Assays (PLA), MILLIPLEX® New PLEXpedition™ screening, verified assays, and Mass Spectrometry for cutting-edge biomarker detection and therapeutic advancements. #alwayscurious

PROLIGHT: PoC troponin testing ready for next step With proof-of-performance for its proprietary digital technique for detection of high-sensitive biomarkers even in whole blood, Prolight Diagnostics has taken significant steps forward in the past year. The share however, has experienced extended downwards pressure following the unit issue and subsequent compensation issue for the underwriters. Once the underwriters’ 150m shares have found their way to more sturdy investors, and the company continues to make progress with prototype development and IVDR certification towards launch in 2026, we expect the pressure to ease, and a revaluation that better reflects the long term prospects, where we find support for a fair value of SEK 1.1 – 1.2 per share. Read the full report here: https://lnkd.in/diPZcqzQ #POCtesting #troponin

Source: Bioanalysis Development of LC-MS/MS assay for multiplexed quantitation of nine human drug transporter biomarkers. Aim to assess SLC-mediated DDIs. Method: HILIC-MS/MS methods. Results: Applied in first human study, data consistent with single assays. Conclusion: Multiplex methods useful for evaluating clinical DDI risk across SLCs.

Join the 𝗽𝗿𝗲-𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝘄𝗼𝗿𝗸𝘀𝗵𝗼𝗽 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻𝘀 at the 3rd ALS Drug Development Summit: 💡 Join Fen Huang, Philip Wong and Robert P. Bowser, Ph.D. to deepen understanding of TDP-43 function and discover new clinically relevant biomarker opportunities 💡 Navigate anticipated trial complications stemming from an evolving standard of care, while optimizing the potential of combination therapies with Shiran Zimri, Machelle Manuel and Fred Grossman D.O., FAPA 💡 Collaborate with Angela Genge, MD, FRCP(C), eMBA, Christopher Ocampo, Stacy Lindborg and Marjan Sepassi to evaluate the potential of novel surrogate biomarkers extending beyond ALSFRS-R and debate the most meaningful endpoints based on regulatory requirements Full details can be found here: https://ter.li/3dn781